1	Full title: Special Olympics global report on COVID-19 vaccination and reasons not to vaccinate
2	among adults with intellectual disabilities
3	
4	Short title: Special Olympics global report on COVID-19 vaccination
5	
6	Andrew E. Lincoln ^{1,2} ¶*, Alicia M. Dixon-Ibarra ^{1,3} ¶, John P. Hanley¹¶, Ashlyn L. Smith¹&, Kiki
7	Martin ^{1&} , Alicia Bazzano ^{1&}
8	
9	¹ Special Olympics, Inc., Washington, DC, United States of America
10	² Georgetown University Medical Center, Department of Rehabilitation Medicine, Washington,
11	DC, United States of America
12	³ Oregon State University, College of Public Health and Human Sciences, Corvallis, OR, United
13	States of America
14	
15	* Corresponding author: Andrew Lincoln, E-mail: alincoln@specialolympics.org
16	¶ These authors contributed equally to this work.
17	^{&} These authors also contributed equally to this work

Abstract

18

46

47

19 Introduction: The COVID-19 pandemic has disproportionately affected people with intellectual 20 disabilities worldwide. The objective of this study was to identify global rates of COVID-19 21 vaccination and reasons not to vaccinate among adults with intellectual disabilities (ID) 22 associated with country economic income levels. 23 24 Methods: The Special Olympics COVID-19 online survey was administered in January-February 25 2022 to adults with ID from 138 countries. Descriptive analyses of survey responses include 26 95% margins of error. Logistic regression and Pearson Chi-squared tests were calculated to 27 28 assess associations with predictive variables for vaccination using R 4.1.2 software. 29 Results: Participants (n=3560) represented 18 low (n=410), 35 lower-middle (n=1182), 41 upper-30 middle (n=837), and 44 high (n=1131) income countries. Globally, 76% (74.8-77.6%) received a 31 COVID-19 vaccination while 49.5% (47.9-51.2%) received a COVID-19 booster. Upper-middle 32 (93% (91.2-94.7%)) and high-income country (94% (92.1-95.0%)) participants had the highest 33 rates of vaccination while low-income countries had the lowest rates (38% (33.3-42.7%)). In 34 multivariate regression models, country economic income level (OR = 3.12, 95% CI [2.81, 35 3.48]), age (OR = 1.04, 95% CI [1.03, 1.05]), and living with family (OR = 0.70, 95% CI [0.53, 36 0.92]) were associated with vaccination. Among LLMICs, the major reason for not vaccinating 37 was lack of access (41.2% (29.5-52.9%)). Globally, concerns about side effects (42%, (36.5-38 48.1%)) and parent/guardian not wanting the adult with ID to vaccinate (32% (26.1-37.0%)) 39 were the most common reasons for not vaccinating. 40 41 Conclusion: Adults with ID from low and low-middle income countries reported fewer COVID-42 19 vaccinations, suggesting reduced access and availability of resources in these countries. 43 Globally, COVID-19 vaccination levels among adults with ID were higher than the general 44 45 population. Interventions should address the increased risk of infection for those in congregate

living situations and family caregiver apprehension to vaccinate this high-risk population.

- 48 Key words (5-8): Special Olympics, COVID-19, vaccination, reasons not to vaccine, global,
- 49 intellectual disabilities

Introduction

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

The COVID-19 pandemic has impacted people with intellectual disabilities (ID) across the world. Intellectual disability originates during early human development and is defined by significant limitations in intellectual functioning and adaptive functioning in conceptual, social, and practical domains (1). People with ID have a higher risk of contracting COVID-19, have poorer health outcomes than the general public, and are on average six times more likely than the general population to die from COVID-19 following hospital admission (2–5). COVID-19 was the leading cause of death among those with intellectual and developmental disabilities in 2020 (6). People with specific diagnoses associated with ID are particularly prone to increased risk of hospitalization and death, including those with Down syndrome, Autism, cerebral palsy, and fragile X syndrome (7–11). There are numerous reasons why people with ID are particularly vulnerable to experiencing severe COVID-19 illness and death (12). Specifically, people with ID may have difficulty accessing care as readily as the general population (13,14). Some live in congregate settings in which COVID-19 has spread more easily (15,16). People with ID are also much more likely to have preexisting conditions that raise the likelihood of experiencing severe outcomes following COVID-19 infection, such as hereditary and cardiac conditions, inborn errors of metabolism, respiratory conditions, and obesity (12). Finally, people with ID may have more challenges with risk mitigation measures, such as masking and distancing (17).

The increased risk of COVID-19 and its consequences make people with ID a particularly important group for vaccination. However, global use of vaccines during the COVID-19 pandemic has differed based on regional public health efforts, allocation of vaccines, type of vaccine, and vaccine acceptance. In low-income nations, challenges in COVID-19 testing and vaccine availability, distribution, and administration are barriers to controlling the spread of

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

the epidemic (18). Further, COVID-19 protocols for preventing, mitigating, and treating/managing infection are largely based upon the general population without considering their effects on persons with ID. These practices have resulted in pandemic-related disparities among those with ID, including poorer physical and mental health (19). Overall, social disparities may have an outsized effect on health outcomes, healthcare access, and basic social determinants of health including food availability, safe housing, and school and work accommodations.

Enhancing equity of persons with ID in the tracking of vaccine uptake and pandemicrelated health outcomes is paramount (20). This can be achieved through partnerships with the disability community and disability organizations. Special Olympics is an international nonprofit organization that provides sports competition and promotes health, education and leadership opportunities to over five million people with ID in 200 countries (21). Early in the COVID-19 pandemic, Special Olympics recognized the potential increased risk for people with ID and created resources to help participants stay healthy and maintain connections among the Special Olympics community. Special Olympics compiled and disseminated accessible resources to program participants and the larger community on topics such as healthy behaviors during COVID-19 (e.g., handwashing, wearing a face mask), resources designed to help participants maintain fitness levels at home, and other virtual activities to maintain social connections with participants, coaches, and friends (22). Prevention activities and the promotion of COVID-19 vaccination were largely carried out at the local level across the world, including low- and highincome countries. Among the general population, COVID-19 infection, use of prevention strategies, and vaccination varied by country economic levels (23–25). Special Olympics's

presence across countries with varying economic levels drove the need to better understand global characteristics of the COVID-19 pandemic among adults with ID.

The objective of this study was to investigate global rates of COVID-19 vaccination and reasons not to vaccinate among adults with intellectual disabilities relative to World Bank country economic income levels.

Methods

The Special Olympics COVID-19 survey was conducted with an online sample of adults with intellectual disabilities 18 years or older who participated in Special Olympics sport, health, schools/education, or leadership programming in 138 countries. Local staff distributed the survey to Special Olympics participants and families. The survey was developed via the Qualtrics platform (Qualtrics, Provo, UT) and remained open for responses from January through February 2022. Questions were self-reported by adults with ID, though proxy responses from family members/caregivers or staff/volunteers were also accepted. The voluntary survey included questions regarding demographics, disability characteristics, COVID-19 vaccination, and reasons for non-vaccination. COVID-19 vaccination was measured by asking participants if they received a COVID-19 vaccine. Those who had not received a COVID-19 vaccination or planned to receive it were asked what the reasons were for their decision.

Data across 138 countries were categorized by the World Bank economic income levels of low-income country (LIC), lower-middle income country (LMIC), upper-middle income country (UMIC), and high-income country (HIC) for primary analyses (26). Analyses were conducted to examine COVID-19 vaccination by diagnosis. Descriptive statistics were calculated as count and proportion of responses. For all proportions, 95% margins of error were calculated

(27). Logistic regression was performed to highlight the associations between demographic variables and country economic income level with COVID-19 vaccination rates. We chose a priori to include demographic variables in the regression model while considering other interpersonal (e.g., living situation) and macro (e.g., country economic level) variables. Pearson Chi-squared tests estimated differences in vaccine acceptance across low and lower-middle income countries (LLMIC) compared to upper-middle and high-income countries (UMHIC). Analyses were performed using R version 4.1.2 (R Foundation for Statistical Computing; Vienna, Austria). This investigation was reviewed by the Oregon State University Institutional Review Board, which determined that it does not meet the definition of human subjects research under the regulations set forth by the Department of Health and Human Services 45 CFR 46.

Results

In total, 3560 individuals from 138 countries (181 country and state-level Special Olympics Programs) responded to the survey. Survey respondents represented 18 LICs (n=410), 35 LMICs (n=1182), 41 UMICs (n=837), and 44 HICs (n=1131). Survey respondents included adults with ID (38.3%), family/caregiver responding on behalf of an adult with ID (39.1%), and program staff/volunteers responding on behalf of an adult and ID (22.6%). The median age across adults with ID was 25 years (Q1-Q3: 21-33 years) with 59.0% male. Most adults with ID (82.9%) lived with family. Participant demographics stratified by World Bank country economic levels are presented in Table 1.

Table 1. Global Survey Respondent Characteristics by World Bank Economic Income Level (%, 95% Margin of Error)^a

138

139140

141

142

143

144

	Low-	Lower-Middle	Upper-Middle	High-	
	Income	Income	Income	Income	Total
	(n=410)	(n=1182)	(n=837)	(n=1131)	(n=3560)
Median Age	23	24	26	30	25
(years), (Q1-Q3)	(20-26)	(20-28)	(21-34)	(24-38)	(21-33)
Sex					
	57.8%	60.0%	62.0%	56.1%	59.0%
Male	(53.0-62.6%)	(57.2-62.8%)	(58.7-65.3%)	(53.3-59.0%)	(57.4-60.6%)
	42.0%	39.7%	37.5%	43.3%	40.6%
Female	(37.2-46.7%)	(36.9-42.5%)	(34.2-40.8%)	(40.4-46.2%)	(39.0-42.2%)
Living arrangemen	t				
Live with	86.3%	86.5%	87.1%	74.8%	82.9%
family	(83.0-89.7%)	(84.5-88.4%)	(84.8-89.4%)	(72.3-77.3%)	(81.7-84.1%)
Live on own	5.1%	4.7%	5.4%	14.1%	7.9%
	(3.0-7.3%)	(3.5-5.9%)	(3.8-6.9%)	(12.0-16.1%)	(7.0-8.7%)
Live in group	8.0%	4.1%	3.0%	7.0%	5.2%
home	(5.4-10.7%)	(3.0-5.3%)	(1.8-4.1%)	(5.5-8.5%)	(4.5-6.0%)
Other	0.5%	4.7%	4.5%	4.2%	4.0%
	(0.0-1.2%)	(3.5-5.9%)	(3.1-6.0%)	(3.0-5.3%)	(3.4-4.7%)
Diagnoses					
Autism	28.8%	15.4%	15.4%	22.3%	19.1%
	(24.4-33.2%)	(13.3-17.5%)	(13.0-17.9%)	(19.9-24.7%)	(17.8-20.4%)
Down	42.7%	29.2%	30.5%	21.3%	28.5%
syndrome	(37.9-47.5%)	(26.6-31.8%)	(27.3-33.6%)	(18.9-23.7%)	(27.1-30.0%)
Fragile X	7.3%	3.9%	1.9%	5.3%	4.3%
	(4.8-9.8%)	(2.8-5.0%)	(1.0-2.8%)	(4.0-6.6%)	(3.6-4.9%)
Cerebral Palsy	10.7%	8.3%	3.7%	5.5%	6.6%
	(7.7-13.7%)	(6.7-9.9%)	(2.4-5.0%)	(4.2-6.8%)	(5.8-7.4%)
Other ID	13.2%	44.9%	49.2%	47.6%	43.1%
	(9.9-16.4%)	(42.1-47.8%)	(45.8-52.6%)	(44.7-50.5%)	(41.5-44.7%)

^aRespondents from 181 Special Olympics programs across 138 countries

Globally, 76.2% (74.8-77.6%) of participants received a COVID-19 vaccination while 49.5% (47.9-51.2%) received a COVID-19 booster (Table 2). Other ID (81.0%, 54.2%), Autism

(76.1%, 46.6%) and Down syndrome (75.0%, 49.8%) were the diagnoses with higher levels of vaccine and booster receipt, respectively. COVID-19 vaccination status varied by economic levels with UMIC and HIC respondents having the highest rates (93.0% (91.2-94.7%) and 93.5% (92.1-95.0%), respectively), while LIC respondents reported the lowest proportion of vaccination (38.0% (33.3-42.7%)). This trend continued for COVID-19 booster vaccinations with UMIC and HIC respondents having the highest proportion (67.0% (63.8-70.2%) and 75.2% (72.7-77.7%), respectively) and LIC respondents with the lowest proportion (14.7% (11.3-18.1%)). Figure 1 displays the receipt of COVID-19 vaccinations and boosters by World Bank economic levels.

Table 2. Receipt of COVID-19 Vaccine and Booster by Intellectual Disability and Country Income Level (%, 95% MoE)

	Received COVID-19	Received COVID-19
	vaccine	booster
Diagnosis*		
Autism (n=681)	76.1 (72.9-79.3)	46.6 (42.9-50.4)
Down Syndrome (n=1016)	75.0 (72.3-77.6)	49.8 (46.7-52.9)
Fragile X (n=152)	68.2 (60.8-75.6)	34.4 (26.9-42.0)
Cerebral Palsy (n=235)	55.8 (49.4-62.2)	34.8 (28.6-40.9)
Other ID (n=1535)	81.0 (79.0-83.0)	54.2 (51.7-56.7)
Country Income Level*		
Low-Income (n=410)	38.0 (33.3-42.7)	14.7 (11.3-18.1)
Lower-Middle Income (n=1182)	61.2 (58.4-63.9)	24.7 (22.2-27.1)
Upper-Middle Income (n=837)	93.0 (91.2-94.7)	67.0 (63.8-70.2)
High-Income (n=1131)	93.5 (92.1-95.0)	75.2 (72.7-77.7)
Total (n=3560)	76.2 (74.8-77.6)	49.5 (47.9-51.2)

^{*} p<0.05 by Pearson Chi-square test

Fig 1. Receipt of COVID-19 Vaccine and Booster by Country Economic Income Level.

Univariate models of vaccination identified age and economic level to be positively associated with vaccination while living with family and having fragile X syndrome or cerebral palsy were inversely associated with vaccination (Table 3). In the multivariate logistic regression model, age (OR=1.04 per year [1.03, 1.05]), country economic level (OR=3.12 [2.81, 3.48]), and living with family (OR=0.70 [0.53, 0.92]) remained associated with vaccination status.

Table 3. Univariate and multivariate logistic regression models of COVID-19 vaccination among Special Olympics global survey respondents (n=3560).

Variables	Unadjusted Odds Ratio	Adjusted Odds Ratio	
	[95% CI]	[95% CI]	
Age (year)	1.08 [1.07, 1.09]***	1.04 [1.03, 1.05] ***	
Sex (male)	1.15 [0.98, 1.34]	1.20 [1.00, 1.43]	
Country economic income level	3.39 [3.07, 3.76] ***	3.12 [2.81, 3.48] ***	
Live with family	0.53 [0.41, 0.66] ***	0.70 [0.53, 0.92] *	
Athlete versus proxy as respondent	1.05 [0.90, 1.23]	0.97 [0.81, 1.16]	
Diagnosis			
Autism	0.99 [0.82, 1.21]	1.32 [0.72, 2.55]	
Down syndrome	0.91 [0.77, 1.07]	1.41 [0.76, 2.78]	
Fragile X	0.66 [0.46, 0.94]*	0.76 [0.37, 1.66]	
Cerebral palsy	0.36 [0.28, 0.48] ***	0.51 [0.26, 1.03]	
Other	1.61[1.37, 1.89] ***	1.21 [0.65, 2.42]	

Note: * P < 0.05, ** P < 0.01, *** P < 0.001.

Globally, among those not vaccinated for COVID-19, respondents in LLMICs reported a near threefold higher willingness to vaccinate (74.1% (70.9-77.3%)) compared to UMHICs (26.5% (19.0-34.0%)) ($\chi^2 = 111.4$, p < 0.001) (Table 4). The primary reasons to not vaccinate

differed among adults with ID in LLMICs and UMHICs (p<0.05 by Pearson Chi-square test). In LIC, the most common reason for not vaccinating was having no access to vaccination (41.2% (29.5-52.9%)). Globally, the most common reasons for not vaccinating were concerns about side effects (42.3%, (36.5-48.1%)) and parent/guardian not wanting the adult with ID to vaccinate (31.5% (26.1-37.0%)).

Table 4. COVID-19 Vaccination Acceptance Among Unvaccinated Respondents and Reasons to Not Vaccinate (%, 95% Margin of Error).

	Low- Income	Lower-Middle Income	Upper-Middle Income	High-Income	Total
Plan to vaccinate	n=253	n=458	n=59	n=73	n=843
Yes	73.1%	74.7%	35.6%	19.2%	66.7%
	(67.7-78.6%)	(70.7-78.7%)	(23.4-47.8%)	(10.1-28.2%)	(63.5-69.8%)
No	7.9%	5.2%	30.5%	53.4%	12.0%
	(4.6-11.2%)	(3.2-7.3%)	(18.8-42.3%)	(42.0-64.9%)	(9.8-14.2%)
Not sure	19.0%	20.1%	33.9%	27.4%	21.4%
	(14.1-23.8%)	(16.4-23.8%)	(21.8-46.0%)	(17.2-37.6%)	(18.6-24.1%)
Reasons to not vaccinate	n=68	n=116	n= 38	n=57	n=279
Vaccine not safe*	16.2%	25.0%	34.2%	47.4%	28.7%
	(7.4-24.9%)	(17.1-32.9%)	(19.1-49.3%)	(34.4-60.3%)	(23.4-34.0%)
Concerned about side	19.1%	40.5%	60.5%	61.4%	42.3%
effects*	(9.8-28.5%)	(31.6-49.5%)	(45.0-76.1%)	(48.8-74.0%)	(36.5-48.1%)
Vaccine will not work*	7.4%	9.5%	34.2%	33.3%	17.2%
	(1.1-13.6%)	(4.2-14.8%)	(19.1-49.3%)	(21.1-45.6%)	(12.8-21.6%)
Distrust government*	7.4%	5.2%	18.4%	28.1%	12.2%
	(1.1-13.6%)	(1.1-9.2%)	(6.1-30.7%)	(16.4-39.7%)	(8.3-16.0%)
Distrust vaccine	4.4%	0.9%	18.4%	28.1%	9.7%
manufacture*	(0.0-9.3%)	(0.8-2.5%)	(6.1-30.7%)	(16.4-39.7%)	(6.2-13.1%)

Prior negative vaccine	1.5%	6.0%	15.8%	19.3%	9.0%
experience*	(0.0-4.3%)	(1.7-10.4%)	(4.2-27.4%)	(9.1-29.5%)	(5.6-12.3%)
Not enough information about	7.4%	31.9%	18.4%	26.3%	22.9%
the vaccine	(1.1-13.6%)	(23.4-40.4%)	(6.1-30.7%)	(14.9-37.7%)	(18.0-27.9%)
No access to vaccine*	41.2%	7.8%	2.6%	0.0%	13.6%
	(29.5-52.9%)	(2.9-12.6%)	(0.0-7.7%)	(0.0-0.0%)	(9.6-17.6%)
Religious objection*	1.5%	2.6%	2.6%	26.3%	7.2%
	(0.0-4.3%)	(0.0-5.5%)	(0.0-7.7%)	(14.9-37.7%)	(4.1-10.2%)
Do not have transportation	16.2%	0.9%	2.6%	0.0%	4.7%
	(7.4-24.9%)	(0.0-2.5%)	(0.0-7.7%)	(0.0 - 0.0%)	(2.2-7.1%)
Don't know where to get	7.4%	0.0%	0.0%	0.0%	1.8%
vaccinated	(1.1-13.6%)	(0.0 - 0.0%)	(0.0-0.0%)	(0.0-0.0%)	(0.2-3.3%)
Do not like needles	17.6%	31.0%	15.8%	17.5%	22.9%
	(8.6-26.7%)	(22.6-39.5%)	(4.2-27.4%)	(7.7-27.4%)	(18.0-27.9%
Parent/ guardians do not want	26.5%	32.8%	23.7%	40.4%	31.5%
me to vaccinate	(16.0-37.0%)	(24.2-41.3%)	(10.2-37.2%)	(27.6-53.1%)	(26.1-37.0%
Other	1.5%	6.0%	7.9%	12.3%	6.5%
	(0.0-4.3%)	(1.7-10.4%)	(0.0-16.5%)	(3.8-20.8%)	(3.6-9.3%)

^{*} P < 0.05 by Pearson Chi-square test

Discussion

This study identified an association between country economic level and COVID-19 vaccination and reasons for not accepting vaccine among adults with ID. Participants from LLMICs reported fewer COVID-19 vaccinations than those from UMHICs and a higher willingness to vaccinate among those who are not yet vaccinated. The most common reasons for not vaccinating offer opportunities to address concerns about vaccine side effects and family caregivers' apprehension to vaccinate this high-risk population.

Over 75% of adults with ID in the current study were vaccinated against COVID-19 compared to 60% of the global population during the same time period (28). The relatively higher rates of COVID-19 vaccination among adults with ID in UMHICs suggest evidence of effective public health polices and favorable vaccine acceptance. At the time of this study, governments across the world implemented universal policies for vaccine delivery for vulnerable populations(29). The high rates of vaccination found in our study are compatible with favorable vaccine uptake among those with ID reported by Hatton et al. (83.5% vaccination rate) and ladorala et al. (87.0% of the participants willing to get the COVID-19 vaccine) (30,31).

Despite overall high rates of vaccination among adults with ID, there were dramatic differences in vaccination across country economic levels. Lower overall vaccination in LICs compared to HICs is consistent with global COVID-19 vaccine dosages administered. As of January 2, 2022, *Our World in Data* reported higher levels of COVID-19 vaccine doses administered among UMICs (169.73 per 100 people) and HICs (166.18) compared to LMICs (84.12) and LICs (10.67)(32). Such findings suggest a lack of resources and infrastructure to vaccinate large populations among many LLMICs (33). As shown by the rates of under-

vaccinated children in LLMICs, vaccine infrastructure may be inadequate for large scale pandemic response (33).

Among those not vaccinated, more adults with ID from LLMICs planned to receive the COVID-19 vaccine compared to UMHICs. Among the unvaccinated population overall, LLMICs generally show higher willingness to accept vaccines than higher income countries (34–36). However, a recent study indicates growing pockets of vaccine hesitancy (37). As vaccines become more accessible to LLMIC, providers should focus communication on building trust, working with trusted stakeholders (e.g., community health workers), and engaging in broad community outreach to reduce vaccine hesitancy and rebuild confidence in vaccination programs for vulnerable and underserved communities (36).

Our findings document the most common reasons that adults with ID did not vaccinate across multiple levels of the sociological framework (38). Vaccination campaigns that target multiple levels of the socioecological model, focus on dialogue-based communication, and include community stakeholders yield better outcomes (37). At the individual level, concerns about vaccine side-effects and safety were top reasons for not receiving a COVID-19 vaccine across country economic levels. However, higher rates of respondents in UMHICs expressed concerns about side effects and safety than LLMICs. Those in UMHICs also expressed skepticism that the vaccine would work, which is consistent with prior research (39). At the interpersonal level of influence, the decision to vaccinate was significantly influenced by caregivers. Globally, parent/guardian restriction for vaccination was a primary reason those with ID were not vaccinating for COVID-19. These results complement Iadorola et al.'s (2022) study where those making decisions on behalf of a person with ID had more vaccine hesitancy than those with ID themselves (31). These collective findings highlight the need to provide vaccine

outreach and education tailored to caregivers' apprehension towards COVID-19 vaccination.

Providing clear information about vaccine risks and incorporating trusted sources of information, including health care providers, may improve vaccine uptake worldwide for those with ID.

This study has several limitations. Findings are from a sample of adults with ID who participate in Special Olympics programming and may not be generalizable to the broader population of persons with ID. The study population includes 181 countries and states with Special Olympics affiliates but is not representative of all countries within economic levels. Because the survey was online, participants without internet access could not be included and likely contributed to underestimates of vaccination. As COVID-19 vaccination were self-reported, the vaccination type and dosage were not available for analysis. Nonetheless, this is the largest study of COVID-19 vaccination among people with ID to date that included representation from three-fourths of the world's countries.

Conclusion

This global study identified a significant association of country economic level on rates of COVID-19 vaccination and reasons for not accepting vaccine among adults with ID. Adults with ID from low and low-middle income countries reported fewer COVID-19 vaccinations, and indicated that the reason for not vaccinating was reduced access. Globally, COVID-19 vaccination levels among adults with ID were higher than the general population. Findings support the need to implement public health interventions that address family caregivers' apprehension to vaccinate this high-risk population.

Acknowledgments

The authors would like to thank the Special Olympics program staff around the world for their assistance in collecting this information.


References

- 1. Tassé M, Luckasson R, Schalock R. The Relation Between Intellectual Functioning and Adaptive Behavior in the Diagnosis of Intellectual Disability. Intellectual and Developmental Disabilities. 2016 Dec 1;54:381–90.
- 2. Nygren M, Lulinski A. State of the Science on COVID-19 and People with IDD [Research brief]. American Association on Intellectual and Developmental Disabilities. 2020;
- 3. Turk MA, Landes SD, Formica MK, Goss KD. Intellectual and developmental disability and COVID-19 case-fatality trends: TriNetX analysis. Disability and Health Journal. 2020 Jul 1;13(3):100942.
- 4. Henderson A, Fleming M, Cooper SA, Pell J, Melville C, MacKay D, et al. COVID-19 infection and outcomes in a population-based cohort of 17,173 adults with intellectual disabilities compared with the general population [Internet]. medRxiv; 2021 [cited 2022 May 27]. p. 2021.02.08.21250525. Available from: https://www.medrxiv.org/content/10.1101/2021.02.08.21250525v1
- Gleason, Jonathan, Ross, Wendy, Fossi, Alexander, Blonsky, Heather, TobiasJane, StephensMary. The Devastating Impact of Covid-19 on Individuals with Intellectual Disabilities in the United States. NEJM Catalyst Innovations in Care Delivery [Internet]. 2021 Mar 5 [cited 2022 Apr 6]; Available from: https://catalyst.nejm.org/doi/full/10.1056/CAT.21.0051
- 6. Landes SD, Finan JM, Turk MA. COVID-19 mortality burden and comorbidity patterns among decedents with and without intellectual and developmental disability in the US. Disability and Health Journal. 2022 Sep;101376.
- 7. Clift AK, Coupland CAC, Keogh RH, Hemingway H, Hippisley-Cox J. COVID-19 Mortality Risk in Down Syndrome: Results From a Cohort Study of 8 Million Adults. Ann Intern Med. 2021 Apr 20:174(4):572–6.
- 8. Malle L, Gao C, Hur C, Truong HQ, Bouvier NM, Percha B, et al. Individuals with Down syndrome hospitalized with COVID-19 have more severe disease. Genet Med. 2021 Mar;23(3):576–80.
- 9. Altable M. Neuroinflammation links COVID-19 and fragile X syndrome: Role of MMP-9, IGF-1, IL-10, metformin, statins and curcumin. Qeios [Internet]. 2021 Feb 17 [cited 2022 May 24]; Available from: https://www.qeios.com/read/KO4C77
- 10. Krieger I, Erez G, Weinstein O, Cohen AD, Tzur Bitan D. COVID-19 Morbidity Among Individuals with Autistic Spectrum Disorder: A Matched Controlled Population-Based Study. J Autism Dev Disord [Internet]. 2021 Jul 8 [cited 2022 May 24]; Available from: https://doi.org/10.1007/s10803-021-05187-2

- 11. Brandenburg JE, Fogarty MJ, Sieck GC. Why individuals with cerebral palsy are at higher risk for respiratory complications from COVID-19. Journal of Pediatric Rehabilitation Medicine. 2020 Jan 1;13(3):317–27.
- 12. Courtenay K, Perera B. COVID-19 and people with intellectual disability: impacts of a pandemic. Irish Journal of Psychological Medicine. 2020 Sep;37(3):231–6.
- 13. Baumbusch J, Moody E, Hole R, Jokinen N, Stainton T. Using Healthcare Services: Perspectives of Community-Dwelling Aging Adults With Intellectual Disabilities and Family Members. Journal of Policy and Practice in Intellectual Disabilities. 2019;16(1):4–12.
- 14. Doherty AJ, Atherton H, Boland P, Hastings R, Hives L, Hood K, et al. Barriers and facilitators to primary health care for people with intellectual disabilities and/or autism: an integrative review. BJGP Open [Internet]. 2020 Aug 1 [cited 2022 Apr 4];4(3). Available from: https://bjgpopen.org/content/4/3/bjgpopen20X101030
- 15. Landes SD, Turk MA, Formica MK, McDonald KE, Stevens JD. COVID-19 outcomes among people with intellectual and developmental disability living in residential group homes in New York State. Disability and Health Journal. 2020 Oct 1;13(4):100969.
- 16. Landes SD, Turk MA, Wong AWWA. COVID-19 outcomes among people with intellectual and developmental disability in California: The importance of type of residence and skilled nursing care needs. Disability and Health Journal. 2021 Apr 1;14(2):101051.
- 17. Doody O, Keenan PM. The reported effects of the COVID-19 pandemic on people with intellectual disability and their carers: a scoping review. Annals of Medicine. 2021 Jan 1;53(1):786–804.
- 18. Sheikh AB, Pal S, Javed N, Shekhar R. COVID-19 Vaccination in Developing Nations: Challenges and Opportunities for Innovation. Infectious Disease Reports. 2021 Jun;13(2):429–36.
- 19. Taggart L, Mulhall P, Kelly R, Trip H, Sullivan B, Wallén EF. Preventing, mitigating, and managing future pandemics for people with an intellectual and developmental disability Learnings from COVID-19: A scoping review. Journal of Policy and Practice in Intellectual Disabilities. 2022;19(1):4–34.
- 20. Andrews EE, Ayers KB, Brown KS, Dunn DS, Pilarski CR. No body is expendable: Medical rationing and disability justice during the COVID-19 pandemic. American Psychologist. 2021;76(3):451–61.
- 21. Reach Report [Internet]. Resources. [cited 2022 Jun 24]. Available from: https://resources.specialolympics.org/governance/reach-report
- 22. Temple VA. COVID-19 Pandemic and Individuals With Intellectual Disability: Special Olympics as an Example of Organizational Responses and Challenges. Adapted Physical Activity Quarterly. 2022 Jan 20;1(aop):1–18.

- 23. Valero M, Valero-Gil JN. Determinants of the number of deaths from COVID-19: differences between low-income and high-income countries in the initial stages of the pandemic. International Journal of Social Economics. 2021 Jan 1;48(9):1229–44.
- 24. Duan Y, Shi J, Wang Z, Zhou S, Jin Y, Zheng ZJ. Disparities in COVID-19 Vaccination among Low-, Middle-, and High-Income Countries: The Mediating Role of Vaccination Policy. Vaccines. 2021 Aug;9(8):905.
- 25. Walker P, Whittaker C, Watson O, Baguelin M, Ainslie K, Bhatia S, et al. Report 12: The global impact of COVID-19 and strategies for mitigation and suppression [Internet]. 19. 2020 Mar [cited 2022 Jun 13]. Available from: http://spiral.imperial.ac.uk/handle/10044/1/77735
- 26. World Bank Country and Lending Groups World Bank Data Help Desk [Internet]. [cited 2022 May 25]. Available from: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519
- 27. Isserlis L. On the Value of a Mean as Calculated from a Sample. Journal of the Royal Statistical Society. 1918 Jan;81(1):75.
- 28. COVID-19 Data Explorer [Internet]. Our World in Data. [cited 2022 Aug 8]. Available from: https://ourworldindata.org/coronavirus-data-explorer
- 29. COVID-19 vaccination policy [Internet]. Our World in Data. [cited 2022 Aug 5]. Available from: https://ourworldindata.org/grapher/covid-vaccination-policy
- 30. Hatton C, Bailey T, Bradshaw J, Caton S, Flynn S, Gillooly A, et al. The willingness of UK adults with intellectual disabilities to take COVID-19 vaccines. Journal of Intellectual Disability Research. 2021;65(11):949–61.
- 31. Iadarola S, Siegel JF, Gao Q, McGrath K, Bonuck KA. COVID-19 vaccine perceptions in New York State's intellectual and developmental disabilities community. Disability and Health Journal. 2022 Jan 1;15(1):101178.
- 32. Total COVID-19 vaccine doses administered per 100 people [Internet]. Our World in Data. [cited 2022 Aug 5]. Available from: https://ourworldindata.org/grapher/covid-vaccination-doses-per-capita
- 33. Figueroa JP, Bottazzi ME, Hotez P, Batista C, Ergonul O, Gilbert S, et al. Urgent needs of low-income and middle-income countries for COVID-19 vaccines and therapeutics. The Lancet. 2021 Feb 13;397(10274):562–4.
- 34. Patwary MM, Alam MA, Bardhan M, Disha AS, Haque MZ, Billah SM, et al. COVID-19 Vaccine Acceptance among Low- and Lower-Middle-Income Countries: A Rapid Systematic Review and Meta-Analysis. Vaccines. 2022 Mar;10(3):427.

- 35. Solís Arce JS, Warren SS, Meriggi NF, Scacco A, McMurry N, Voors M, et al. COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries. Nat Med. 2021 Aug;27(8):1385–94.
- 36. Bhopal S, Nielsen M. Vaccine hesitancy in low- and middle-income countries: potential implications for the COVID-19 response. Arch Dis Child. 2021 Feb;106(2):113–4.
- 37. Simas C, Larson HJ. Overcoming vaccine hesitancy in low-income and middle-income regions. Nat Rev Dis Primers. 2021 Jun 10;7(1):1–2.
- 38. Latkin C, Dayton LA, Yi G, Konstantopoulos A, Park J, Maulsby C, et al. COVID-19 vaccine intentions in the United States, a social-ecological framework. Vaccine. 2021 Apr 15;39(16):2288–94.
- 39. Sallam M. COVID-19 Vaccine Hesitancy Worldwide: A Concise Systematic Review of Vaccine Acceptance Rates. Vaccines. 2021 Feb;9(2):160.



Figure